Nuveen AMT-Free Municipal Credit Income Fund of Beneficial Interest (NVG)
Market Closed
1 Sep, 20:00
NYSE NYSE Primary NASDAQ $
12. 02
-0.13
-1.07%
$
2.63B Market Cap
0.77% Div Yield
927,064 Volume
$ 12.15
Previous Close 
Want to track NVG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
NervGen Pharma: I Think The Biggest Risks Are Now Behind It
NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial. NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting focus to NVG-291's ability to replicate efficacy in chronic tetraplegia. Objective biomechanical gait analysis showed statistically significant improvements, reinforcing the case for NVG-291's neural recovery over compensatory adaptation.
Seekingalpha | 2 months ago
